他真的不是“药神” 代购的境外抗癌药有效成分为零

Core Viewpoint - The article discusses the case of a counterfeit cancer drug, "安罗替尼" (Anlotinib), which was falsely marketed as an imported version, highlighting the ongoing issues of drug safety and regulation in China [1][3][6]. Group 1: Drug Counterfeiting Case - A pharmaceutical company discovered that its original cancer drug, Anlotinib, was being counterfeited and sold as an "imported version" without authorization [1][3]. - The counterfeit drug was found to contain zero active ingredients, posing significant health risks to patients [5][6]. - The counterfeit operation was traced back to a person named Mao, who was involved in importing and distributing the fake drug in China [8][10]. Group 2: Impact on Patients - Before being included in the medical insurance system, the cost of Anlotinib was approximately 10,000 yuan per month, which was reduced to around 1,000 yuan after inclusion [3]. - Patients with conditions not covered by insurance still faced financial burdens, leading some to seek cheaper alternatives through unofficial channels [3][6]. - The counterfeit drug was sold at a lower price but lacked any therapeutic effect, misleading patients desperate for treatment [12][14]. Group 3: Legal and Regulatory Framework - The case highlights the importance of protecting intellectual property and ensuring drug safety, as counterfeit drugs can severely impact patient health and undermine pharmaceutical innovation [16][18]. - The legal framework has evolved, with the introduction of the "Crime of Impairing Drug Management" to address issues related to counterfeit drugs more effectively [21][22]. - The court ultimately sentenced Mao to one year in prison for his role in the counterfeit drug operation, reflecting the legal system's response to such crimes [27][28].